Core Insights - The article discusses the investment potential of CDTX, highlighting a beneficial long position in its shares [1]. Group 1 - The analyst expresses a personal opinion on CDTX, indicating a positive outlook based on their own analysis [1]. - There is no compensation received for the article, emphasizing the independence of the analysis [1]. - The article does not provide specific investment recommendations, focusing instead on the author's views [2].

Cidara Therapeutics (CDTX) Q2 2025 Earnings Call August 07, 2025 05:00 PM ET Speaker0Afternoon, and welcome to the Sedara Therapeutics Second Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note that the event is being recorded. I would now like to turn the conference over to Brian Ritchie with LifeSci Advisors.Please go ahead.Speaker1Thank you, operator, and good afternoon, e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36912 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation ...

Exhibit 99.1 SAN DIEGO, August 7, 2025 — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided recent business updates. ® "The highly compelling results of our Phase 2b NAVIGATE trial for CD388 and subsequent financing puts us in a position of strength to execute on our Phase 3 plan to examine ...

Core Insights - Cidara Therapeutics, Inc. will report its Q2 2025 financial results and operational highlights on August 7, 2025, followed by a conference call at 5:00 PM Eastern Time [1][2] Company Overview - Cidara Therapeutics is focused on developing drug-Fc conjugates (DFCs) using its proprietary Cloudbreak platform, with its lead candidate CD388 aimed at universal prevention of influenza [3] - CD388 received Fast Track Designation from the FDA in June 2023 and positive top-line results from its Phase 2b NAVIGATE clinical trial were announced in June 2025 [3] - The company has also developed additional DFCs for oncology, including CBO421, which received IND clearance in July 2024 to target CD73 in solid tumors [3]

Core Points - Cidara Therapeutics, Inc. granted non-qualified stock option awards and restricted stock units (RSUs) totaling 12,100 shares to two new employees under the 2020 Inducement Incentive Plan, with a grant date of June 30, 2025 [1][2] - The stock option has an exercise price of $48.71 per share, equal to the closing price on the grant date, and will vest over four years [1] - The Inducement Plan is specifically for granting equity awards to individuals who were not previously employees or who have had a bona fide period of non-employment [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugates (DFCs), including the lead candidate CD388, aimed at universal prevention of seasonal and pandemic influenza [3] - CD388 received Fast Track Designation from the FDA in June 2023, and the Phase 2b NAVIGATE trial enrollment was completed in December 2024 [3] - The company has also developed additional DFCs for oncology, including CBO421, which received investigational new drug application clearance in July 2024 [3]

Core Insights - The biopharmaceutical industry is characterized by volatile stock movements, with companies often experiencing rapid rallies and sell-offs due to trial data and product developments [1][2] Company Summaries Nektar Therapeutics (NKTR) - Nektar Therapeutics has seen a significant increase in share price following successful Phase 2b trial results for its immunotherapy drug candidate, Rezpeg, which targets conditions like eczema affecting approximately 10 million patients in the U.S. [4][6] - The stock price surged over 300% within five trading days, reaching just under $30 per share, although it remains significantly lower than its all-time high of over $1,500 from early 2018 [5][6] - Analysts are optimistic, with six out of seven rating the stock as a Buy and a consensus price target of $84.17, indicating a potential upside of about 227% [6] Cidara Therapeutics (CDTX) - Cidara Therapeutics experienced a nearly 150% increase in share price following positive Phase 2b trial results for CD388, a non-vaccine treatment for seasonal influenza, which demonstrated a 76% protection rate for 24 weeks [8][9] - The stock reached its highest level since spring 2021, and analysts are bullish, with all nine ratings being Buy, although the company issued $250 million in new stock, which could dilute existing shares [10] GeneDx Holdings Corp. (WGS) - GeneDx has seen a recent stock surge of nearly 40% after announcing a partnership with Galatea Bio for genetic testing and updated guidance from the American Academy of Pediatrics recommending genomic sequencing for children with developmental delays [12][14] - Despite topping analyst predictions for first-quarter sales and raising revenue guidance for FY 2025, the stock had previously plummeted by almost 50% [12][13] - Six out of eight analysts rate WGS as a Buy, but concerns remain regarding its high valuation and competition in the genomic diagnostics space [15]

Company Overview - Cidara Therapeutics, Inc. is a biotechnology company utilizing its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics [1][4] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose [4] - Cidara is headquartered in San Diego, California [4] Recent Developments - Cidara has been added to the Russell 2000® and Russell 3000® Indexes, marking an important milestone for the company [1][3] - The inclusion in these indexes enhances visibility with institutional investors following a successful $400 million financing and positive data from the Phase 2b NAVIGATE trial [3] Clinical Trials and Regulatory Status - CD388 received Fast Track Designation from the U.S. FDA in June 2023 [4] - Enrollment for the Phase 2b NAVIGATE trial was completed in December 2024 [4] - Cidara has developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received investigational new drug application clearance in July 2024 [4]

Group 1 - Cidara Therapeutics, Inc. closed its underwritten public offering of 9,147,727 shares at a price of $44.00 per share, raising gross proceeds of $402.5 million [1] - The offering included the full exercise of the underwriters' option to purchase an additional 1,193,181 shares [1] - The offering was conducted under a shelf registration statement filed with the SEC on May 8, 2025, and declared effective on May 15, 2025 [3] Group 2 - Cidara is utilizing its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, with its lead candidate CD388 aimed at universal prevention of influenza [5] - CD388 received Fast Track Designation from the FDA in June 2023, and the Phase 2b NAVIGATE trial enrollment was completed in December 2024 [5] - Cidara has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received investigational new drug application clearance in July 2024 [5]

Core Insights - Cidara Therapeutics, Inc. has made significant progress with its long-lasting flu prophylactic candidate, CD388, as indicated by positive Phase 2b trial results [1] Company Summary - Cidara Therapeutics is a biotechnology company based in San Diego, focusing on innovative treatments [1] - The company has received a "Buy" rating since February 2025, reflecting confidence in its product pipeline [1] Industry Context - The advancements in flu prophylactics, particularly with CD388, highlight the ongoing innovation within the biotech sector, especially in preventive treatments [1]